AbbVie Inc. ABBV SPXR3KPHARMA
Company Overview
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Why Investors Should Care
Operating margin of 40.0% supports profitability.
Offers a dividend yield of 2.84%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $61.16B (+8.6% YoY); net profit $4.23B.
- Trailing 12 Months Year-on-year growth — revenue +10.2%, earnings +290.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.8%, profit CAGR -29.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.75% |
| 1 Year: | 10.20% |
Compounded Profit Growth
| 5 Years: | -29.06% |
| 1 Year: | 290.40% |
Stock Price Performance
| 1 Year: | +31.24% |
| 6 Months: | +13.18% |
| 3 Months: | +13.67% |
| 1 Month: | +5.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.34 · Neutral
P/E of 72.45 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 2.84%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 72.5.
- Earnings shrank at -29.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 7 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 8 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 608.52 | 32.79 | $225.00B | 0.32% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 6.54B | 6.94B | 7.00B | - | 7.93B | 8.28B | 8.24B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.34B | 15.42B | 15.78B | 16.62B | 15.00B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00B | 4.35B | 5.30B | 4.55B | 4.22B | - |
| Gross Profit | 4.93B | 5.24B | 4.92B | 5.42B | 5.38B | 5.46B | 6.01B | 6.34B | 6.40B | 6.28B | 6.13B | 6.44B | 6.56B | 6.70B | - | - | - | 9.17B | - | - | - | 10.57B | - | - | - | 10.95B | - | - | - | 8.60B | - | - | - | - | 9.34B | 11.08B | 10.47B | 12.07B | 10.78B | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.36B | 5.36B | 5.89B | 6.26B | 6.05B | - |
| Operating Income | 2.36B | - | 2.41B | 2.66B | 2.69B | - | 2.90B | 2.76B | 3.16B | - | 3.01B | 3.40B | 2.62B | - | 3.60B | 752.00M | 3.25B | - | 4.10B | 4.44B | 4.31B | - | 4.72B | 3.29B | 4.60B | - | 2.77B | 4.51B | 2.28B | - | 2.80B | 4.00B | 3.83B | - | 3.98B | 5.72B | 4.58B | 5.81B | 4.73B | 6.43B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.40B | 4.34B | 3.52B | 5.37B | 3.69B | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 700.00M | 740.00M | 739.00M | 714.00M | 717.00M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.66B | 1.55B | 714.00M | 2.67B | 1.04B | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 372.00M | 613.00M | 526.00M | 853.00M | 342.00M | - |
| Net Income | 1.60B | 1.39B | 1.71B | 1.92B | 1.63B | 52.00M | 2.78B | 1.98B | 2.75B | -1.83B | 2.46B | 741.00M | 1.88B | 2.80B | 3.01B | -738.00M | 2.31B | 36.00M | 3.55B | 766.00M | 3.18B | 4.04B | 4.49B | 924.00M | 3.95B | 2.47B | 239.00M | 2.02B | 1.78B | 822.00M | 1.37B | 1.37B | 1.56B | - | 1.29B | 938.00M | 186.00M | 1.82B | 695.00M | 3.61B |
| Diluted EPS | 0.97 | 0.85 | 1.06 | 1.19 | 1.01 | 0.03 | 1.74 | 1.26 | 1.81 | -1.23 | 1.65 | 0.49 | 1.26 | 1.88 | 2.02 | -0.46 | 1.29 | 0.01 | 1.99 | 0.42 | 1.78 | 2.26 | 2.51 | 0.51 | 2.21 | 1.38 | 0.13 | 1.14 | 1.00 | 0.46 | 0.77 | 0.77 | 0.88 | - | 0.72 | 0.52 | 0.10 | 1.02 | 0.39 | 2.03 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.44B | 18.38B | 18.79B | 19.96B | 22.86B | 25.64B | 28.22B | 32.75B | 33.27B | 45.80B | 56.20B | 58.05B | 54.32B | 56.33B | 61.16B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 17.41B | 20.41B | 16.90B | 18.20B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 40.64B | 33.90B | 39.43B | 42.96B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 21.83B | 20.37B | 27.54B | 22.86B |
| Operating Income | 3.62B | 5.82B | 5.66B | 3.41B | 7.54B | 9.34B | 9.54B | 6.38B | 12.98B | 11.36B | 17.92B | 18.81B | 13.54B | 11.89B | 20.09B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | 24.17B | 17.17B | 14.91B | 17.63B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 2.23B | 2.22B | 2.81B | 2.89B |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | 13.48B | 6.25B | 3.72B | 6.60B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 1.63B | 1.38B | -570.00M | 2.36B |
| Net Income | 3.43B | 5.28B | 4.13B | 1.77B | 5.14B | 5.95B | 5.31B | 5.69B | 7.88B | 4.62B | 11.54B | 11.84B | 4.86B | 4.28B | 4.23B |
| Diluted EPS | 2.18 | 3.35 | 2.56 | 1.10 | 3.13 | 3.63 | 3.30 | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 27.01B | 29.20B | 27.51B | 53.05B | 66.10B | 70.79B | 59.35B | 89.11B | 150.56B | - | 138.81B | 134.71B | 135.16B | 133.96B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 28.46B | 33.00B | 25.58B | 29.06B |
| Cash & Equivalents | 10.00M | 27.00M | 5.90B | 9.60B | 8.35B | 8.40B | 5.10B | 9.30B | 7.29B | 39.92B | 8.45B | - | 9.20B | 12.81B | 5.52B | 5.23B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 3.58B | 4.10B | 4.18B | 4.95B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 11.25B | 11.15B | 10.92B | 12.59B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 121.52B | 124.31B | 131.80B | 137.19B |
| Current Liabilities | - | - | 6.78B | 6.88B | 11.39B | 10.89B | 9.78B | 16.64B | 17.24B | 15.59B | 28.66B | - | 29.54B | 37.84B | 38.75B | 43.29B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 67.23B | 84.95B | - | 59.13B | 52.19B | 60.34B | 58.94B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 63.27B | 59.38B | 67.14B | 67.50B |
| Total Equity | - | - | -350.00M | 4.49B | 1.74B | 3.94B | 4.64B | 5.10B | -8.45B | -8.17B | 13.08B | - | 17.25B | 10.36B | 3.33B | -3.27B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 1.81B | 1.82B | 1.83B | 1.84B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | 9.96B | 13.43B | 13.32B | 17.59B | - | 24.94B | 22.84B | 18.81B | 19.03B |
| Investing Cash Flow | - | - | - | - | - | - | -274.00M | -1.01B | 596.00M | -37.56B | - | -623.00M | -2.01B | -20.82B | -6.64B |
| Financing Cash Flow | - | - | - | - | - | -3.93B | -5.51B | -14.40B | 18.71B | -11.50B | - | -24.80B | -17.22B | -5.21B | -12.72B |
| Capital Expenditure | -356.00M | -333.00M | -491.00M | -612.00M | -532.00M | -479.00M | -529.00M | -638.00M | -552.00M | -798.00M | - | -695.00M | -777.00M | -974.00M | -1.21B |
| Free Cash Flow | - | - | - | - | - | - | 9.43B | 12.79B | 12.77B | 16.79B | - | 24.25B | 22.06B | 17.83B | 17.82B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -483.00M | 3.61B | -7.22B | -337.00M |
| Share Buybacks | - | - | 320.00M | 665.00M | 7.59B | 6.03B | 1.41B | 12.01B | 629.00M | 978.00M | 934.00M | 1.49B | 1.97B | 1.71B | 980.00M |
| Dividends Paid | - | - | 2.56B | 2.66B | 3.29B | 3.72B | 4.11B | 5.58B | 6.37B | 7.72B | 9.26B | 10.04B | 10.54B | 11.03B | 11.66B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 70.0% | 62.4% | 70.0% | 70.2% |
| Operating Margin % | 20.8% | 31.6% | 30.1% | 17.1% | 33.0% | 36.4% | 33.8% | 19.5% | 39.0% | 24.8% | 31.9% | 32.4% | 24.9% | 21.1% | 32.8% |
| Net Margin % | 19.7% | 28.7% | 22.0% | 8.9% | 22.5% | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| ROE % | - | -1,507.1% | 91.9% | 101.8% | 130.4% | 128.4% | 104.2% | -67.3% | -96.5% | 35.3% | - | 68.6% | 46.9% | 128.7% | -129.2% |
| ROCE % | - | 28.8% | 25.4% | 21.2% | 17.9% | 16.6% | 17.6% | 15.2% | 17.7% | 9.3% | - | 17.2% | 14.0% | 12.3% | 22.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.46% | 149.49M | $38.19B |
| 2 | Vanguard Capital Management LLC | 6.53% | 115.40M | $29.48B |
| 3 | State Street Corporation | 4.67% | 82.60M | $21.10B |
| 4 | Vanguard Portfolio Management LLC | 2.74% | 48.48M | $12.39B |
| 5 | JPMORGAN CHASE & CO | 2.71% | 47.86M | $12.23B |
| 6 | Geode Capital Management, LLC | 2.66% | 47.00M | $12.01B |
| 7 | Morgan Stanley | 2.20% | 38.90M | $9.94B |
| 8 | Capital Research Global Investors | 1.70% | 30.10M | $7.69B |
| 9 | NORGES BANK | 1.45% | 25.55M | $6.53B |
| 10 | Bank of America Corporation | 1.20% | 21.24M | $5.43B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ABBV
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.…
The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge
Amazon's diversified growth and AI push, AbbVie's pipeline, Alibaba's cloud gains and Lulu's improving margins shape these analyst picks.
Here Are 5 ETFs That Retirees Use to Skip Stock Picking Entirely
Owning two or three dividend ETFs feels like extra protection, but it can quietly leave retirees paying multiple expense ratios for a nearly identical stack of stocks. Here is how the five most popular options actually differ, and why the w…
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
ABBV — Frequently Asked Questions
What is the current share price of AbbVie Inc. (ABBV)?
As of 2026-09-07 16:24 PDT, AbbVie Inc. (ABBV) trades at $256.46 on NYSE. Its 52-week range is $195.41 to $265.97.
What is the market capitalisation of ABBV?
AbbVie Inc. (ABBV) has a market capitalisation of $453.19B on NYSE.
What is the P/E ratio of ABBV?
ABBV trades at a trailing price-to-earnings (P/E) ratio of 72.45. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -73.25.
Does ABBV pay a dividend?
AbbVie Inc. (ABBV) currently offers a dividend yield of 2.84%.
What is the return on equity (ROE) of ABBV?
ABBV has a return on equity (ROE) of -129.24%. Its return on capital employed (ROCE) is 10.47%.
Is ABBV a good stock to buy?
This page provides a data-driven analysis of AbbVie Inc. (ABBV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.